ZURICH, May 12 (Reuters) – Swiss drugmaker Roche has received the CE mark – a ‌European regulatory clearance allowing sale in ‌the region – for its second Elecsys blood test for ​Alzheimer’s disease, it said on Tuesday.

The test was developed with U.S. company Eli Lilly.

• Compared with its already approved pTau181 test, ‌which mainly helps ⁠rule out Alzheimer’s-related amyloid pathology, the newer pTau217 test can both ⁠help confirm and exclude the disease. It is validated for use in both primary ​and specialist ​care.

• The test ​has already received breakthrough ‌device designation from the U.S. FDA.

• Blood tests could speed diagnosis and widen access to treatments such as Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla, as current ‌diagnostic methods are often ​costly or uncomfortable.

• Roche ​said an estimated ​75% of people living with ‌dementia remain undiagnosed.

• The test ​is expected ​to become available in CE-marked markets from July, Olivier Gillieron, life cycle leader ​in cardiometabolic ‌and neurology at Roche told media ​in a call.

(Reporting by Marleen Kaesebier. ​Editing by Mark Potter)